Medical isotope developer IsoRay Medical said that the Weill Cornell Medical Center in New York City has become the first institution to treat recurrent head and neck cancer using its cesium-131 implant.
The implant was performed on August 5 using Vicryl-embedded seeds on a 66-year-old patient. There is no evidence of cancer recurrence to date, according to the Richland, WA-based vendor.
Related Reading
IsoRay's 2009 results dip, September 24, 2009
IsoRay nets FDA OK on seeds, August 18, 2009
IsoRay sales drop, loss narrows, May 18, 2009
IsoRay expands into Canadian market, May 7, 2009
IsoRay, BrachySciences ink deal, February 18, 2009
Copyright © 2009 AuntMinnie.com
